From Hair Loss to Ozempic: This Stock Is Everywhere

August 19, 2025

Hello Investor,

It started with $20 shampoo subscriptions.

Now? This digital health platform is scaling into one of the biggest megatrends in the market — and Wall Street is just starting to catch on.

The company?

  • Q2 revenue: $544.8M, up 73% YoY

  • GAAP net income: $42.5M

  • Subscribers: 2.4M (+31% YoY)

  • Expanding GLP‑1 weight‑loss program as the market normalizes

  • Insiders buying, not selling.

The name is Hims & Hers (HIMS) — and the story is changing fast.

💊 From Vanity Brand to Healthcare Platform

At first, critics wrote Hims off as a niche direct-to-consumer gimmick. But the company has quietly built:

  • 1.5M+ active subscribers across multiple categories

  • An expanding portfolio from dermatology to psychiatry to GLP-1s

  • A low-cost acquisition model fueling recurring revenue

  • The beginnings of a true consumer health platform

What looked like a “fad brand” is becoming a healthcare toll booth for an entire generation.

⚠️ Why We’re Watching Now

  • GLP-1 prescriptions are rolling out on platform

  • Price action has based near $40–45 support

  • Short interest remains elevated (a setup for squeeze potential)

It’s not just hype. It’s a growth story entering scale mode.

🔓 Want the Full Breakdown?

In today’s premium research note, we dive into:

  • The exact price zone we’re watching for accumulation

  • Growth targets based on 2025–2026 fundamentals

  • The macro triggers that could unlock the next leg higher

  • And why this name might be the most underestimated in healthcare

Stay sharp, stay patient — and stay ahead of the crowd.

— StocksTrades.AI Newsletter

Disclaimer: This newsletter is for informational purposes only and does not constitute financial advice. Always conduct your own research before making investment decisions.